64 Results for "

metastatic carcinoma

" in MedChemExpress (MCE) Product Catalog:
Products (64)

64 Results for "metastatic carcinoma" in MCE Product Catalog:

63
63 Publications Verification
Cat. No.: HY-P9906
CAS No.: 216974-75-3
Synonyms: Anti-Human VEGF, Humanized Antibody
Bevacizumab (Anti-Human VEGF, Humanized Antibody) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab possesses immunomodulatory properties. Bevacizumab can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer .
loading...
    loading...
63
63 Publications Verification
Cat. No.: HY-P9906A
CAS No.: 216974-75-3
Target:  

VEGFR

Bevacizumab (Anti-VEGFA) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab (Anti-VEGFA) blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab (Anti-VEGFA) possesses immunomodulatory properties. Bevacizumab (Anti-VEGFA) can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-101488
CAS No.: 1010100-07-8
Purity:  99.85%
CC-885, a cereblon (CRBN) modulator, acts as a molecular glue degrader targeting GSPT1 with a Kd of 350 nM. CC-885 binds to CRBN to alter the substrate specificity of the CRL4 E3 ligase, promoting the ubiquitination and proteasomal degradation of GSPT1, BNIP3L, PLK1, CDK4, IKZF1/3, GSPT2, WIZ, CHD7, GOLM1, CK1α and ETS1. CC-885 induces apoptosis, cell cycle arrest, transcriptional downregulation and antiproliferation in cancer cells. CC-885 is applicable to research related to relapsed/refractory acute myeloid leukemia, MYC-driven tumors, metastatic castration-resistant prostate cancer, multiple myeloma, hepatocellular carcinoma, glioblastoma, VHL-deficient clear cell renal cell carcinoma and non-small cell lung cancer .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-136174
CAS No.: 2381037-82-5
Purity:  99.86%
Target:  

PARP

Research Areas:  

Cancer

RBN-2397 is a potent, accross species and orally active NAD + competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-17473
CAS No.: 550-24-3
Synonyms: Embelic acid; Emberine; NSC 91874
Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P99032
CAS No.: 1228763-95-8
Synonyms: IPH2201
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99016
CAS No.: 1448664-46-7
Synonyms: AGS-22C3
Target:  

ADC Antibodies Nectin-4

Research Areas:  

Cancer

Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10332
CAS No.: 194413-58-6
Synonyms: (Z)-SU5416
Target:  

VEGFR

(Z)-Semaxanib ((Z)-SU5416) is a VEGF receptor tyrosine kinase inhibitor that blocks VEGF signaling through Flk-1/KDR. (Z)-Semaxanib inhibits angiogenesis by preventing new blood vessel formation. (Z)-Semaxanib induces cytotoxicity in liver cancer cells. (Z)-Semaxanib can be used in research on metastatic renal cell carcinoma, gastrointestinal stromal tumors, well-differentiated pancreatic neuroendocrine tumors, and solid tumors .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-107588
CAS No.: 916734-43-5
Purity:  99.94%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109050
CAS No.: 1637771-14-2
Purity:  98.04%
Synonyms: GS-5829
Research Areas:  

Cancer

Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-118487
CAS No.: 939825-12-4
Purity:  98.03%
Research Areas:  

Cancer

OB-24 is a selective small-molecule HO-1 inhibitor (IC50 = 1.9 μM for HO-1 and IC50 for HO-2 >100 μM). OB-24 possesses anti-tumor and anti-metastatic properties. OB-24 can be studies in research such as prostate cancer, melanoma, ovarian carcinoma and lung metastasis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99016B
CAS No.: 1346452-25-2
Research Areas:  

Cancer

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99016A
CAS No.: 1346452-25-2
Research Areas:  

Cancer

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13747
CAS No.: 13909-09-6
Purity:  ≥98.0%
Research Areas:  

Cancer

Semustine is an orally active, blood-brain barrier permeable antitumor alkylating agent with a binding affinity of 1.53 × 10 3 M -1 for guanine and thymine residues in bovine DNA. Semustine undergoes major groove-directed alkylation at guanine residues to form O6-chloroethylguanine and N1-O6-ethanoguanine adducts, and generates dG-dC interstrand crosslinks. Semustine induces partial B- to C-type transition of DNA, base stacking and helical structure distortion, mild dehydration, as well as partial DNA double-strand unwinding. Semustine can be used in research related to Lewis lung cancer, leukemia, Hodgkin's lymphoma, malignant melanoma, glioma, and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-P99406
CAS No.: 2213450-26-9
Synonyms: MCLA 158

Target:  

EGFR

Research Areas:  

Cancer

Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
loading...
    loading...
Cat. No.: HY-164702
Synonyms: Izalontamab Brengitecan
Research Areas:  

Cancer

BL-B01D1 (Izalontamab Brengitecan) is a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, formed by conjugating the EGFR/HER3 bispecific antibody Izalontamab (HY-P99676) to a novel TOP-I inhibitor payload Deruxtecan 2-hydroxypropanamide (HY-153891) via a cleavable linker (Mc-Gly-Gly-Phe-Gly). BL-B01D1 binds to EGFR and HER3 on the surface of tumor cells, mediates endocytosis and releases the payload, inhibits topoisomerase I, blocks DNA replication and RNA synthesis, and disrupts DNA structure. BL-B01D1 induces cell cycle S-phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity, and tumor cell death. BL-B01D1 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-159642
CAS No.: 2800223-30-5
Synonyms: TYRA-300
Target:  

FGFR ERK

Research Areas:  

Metabolic Disease Cancer

Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
loading...
    loading...
Cat. No.: HY-P99384
CAS No.: 1312305-12-6
Synonyms: B-701; MFGR-1877S; RG-7444

Target:  

FGFR

Research Areas:  

Cancer

Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P99758
CAS No.: 2377845-98-0
Synonyms: CS1003

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab shows antitumor activity and can be used for the research of unresectable or metastatic hepatocellular carcinoma .
loading...
    loading...